About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Novel Imaging Agent Accurately Identifies Prostate Cancer Lesions

by Dr. Trupti Shirole on December 5, 2016 at 5:29 PM
Font : A-A+

 Novel Imaging Agent Accurately Identifies Prostate Cancer Lesions

In 2016, more than 180,000 men in the United States are expected to be diagnosed with prostate cancer, and more than 26,000 are likely to die from the disease, suggests the National Cancer Institute.

New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the December issue of The Journal of Nuclear Medicine, the Phase 1 dose-escalation study of Zr-89-desferrioxamine-IAB2M (Zr-89-Df-IAB2M), an anti-PSMA (prostate-specific membrane antigen) minibody, in patients with metastatic prostate cancer shows its effectiveness in targeting both bone and soft tissue lesions.

Advertisement


"This agent is imaged faster than other PSMA-targeting imaging antibodies due to its small size and has been shown to be safe for patients," explains Neeta Pandit-Taskar of the Memorial Sloan Kettering Cancer Center in New York City. "The radiotracer combines a small amount of the radioactive material zirconium-89 with a fragment of an antibody called a minibody. This minibody has anti-PSMA qualities and attaches to overexpression of the enzyme on the exterior of prostate cancer cells, wherever they may have traveled in the body. Particles emitted from the site are then detected by positron emission tomography (PET). The resulting scan highlights 'hot spots' of PSMA overexpression."

She adds, "Using this agent, we can detect the prostate cancer cells that have metastasized to bone - one of the most difficult areas to evaluate using standard methods."
Advertisement

For the study, 18 patients were imaged with the new agent using PET/CT as well as a variety of conventional imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), molecular bone scan (SI), and PET with fluorodeoxyglucose (FDG-PET). Suspected disease sites were then selected and biopsied.

Both skeletal and nodal lesions were detected with Zr-89-Df-IAB2M; scans were positive in 17 of the 18 patients, with bone lesions targeted in nine and soft tissue disease seen in 14. In comparison, bone scans with more traditional agents (Tc-99m-methylene diphosphonate and FDG) were positive for bone lesions in nine and six patients, respectively; for nodal/soft tissue disease, CT and FDG scans were positive in 14 and 10 patients, respectively. In two patients, a single site of disease per patient was identified only by the minibody. In total, Zr-89-Df-IAB2M imaging detected 147 bone and 82 soft-tissue or nodal lesions.

"Results of imaging with this Zr-89 radiolabeled minibody have shown that we are able to detect more disease sites in patients than with conventional imaging," Pandit-Taskar states. "We hope that with further development this technology will help us in earlier and more accurate assessment of disease and assist in clinical decision-making." She points out, "With further validation, this agent could potentially be used for targeted biopsies, which could lead to more appropriate, timely treatment for prostate cancer patients. It may also have potential use in targeted radiotherapy."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
Test Your Knowledge on Sugar Intake and Oral Health
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] Nutrition All Men Need 

Most Popular on Medindia

Drug Side Effects Calculator Find a Doctor Sanatogen Iron Intake Calculator Blood - Sugar Chart Drug - Food Interactions Indian Medical Journals Selfie Addiction Calculator Sinopril (2mg) (Lacidipine) Nutam (400mg) (Piracetam)
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Novel Imaging Agent Accurately Identifies Prostate Cancer Lesions Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests